Reflecting on Real-World Evidence for Durvalumab in Unresectable Stage III NSCLCMay 25th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the PACIFIC and PACIFIC-R studies of durvalumab in patients with unresectable stage III non–small cell lung cancer.
Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell MalignanciesMay 25th 2023
When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.
Tolerability With Brentuximab Vedotin Treatment in Hodgkin LymphomaMay 24th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.
SunRISE Program Incites Optimism About the Future of High-Risk, BCG-Unresponsive NMIBC TreatmentMay 24th 2023
In an interview with Targeted Oncology, Siamak Daneshmand, MD, discussed TAR-200 as seen in the SunRISE-1 trial and the what is up next for the treatment landscape of high-risk BCG-unresponsive non-muscle invasive bladder cancer.
Oncologists Back Legislation to Help Improve Access to Biomarker TestingMay 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
FDA Grants Orphan Drug Designation to Mitazalimab for Pancreatic CancerMay 23rd 2023
Mitazalimab has received an orphan drug designation from the FDA and is currently being investigated in the OPTIMIZE-1 trial in combination with modified FOLFIRINOX for the treatment of patients with pancreatic cancer.
Physicians Discuss When to Use a PARP Inhibitor in mCRPCMay 22nd 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.
Cabozantinib With Nivolumab and Ipilimumab Prolongs PFS in Renal Cell CarcinomaMay 22nd 2023
While cabozantinib, nivolumab, and ipilimumab resulted in a longer progression-free survival among patients with renal cell carcinoma vs nivolumab and ipilimumab alone, more adverse events were observed with the combination.
Updates to NCCN Guidelines for CNS Cancers Pinpoint the Importance of TestingMay 21st 2023
In an interview with Targeted Oncology, Craig Horbinski, MD, PhD, discussed recent recommendations and NCCN guidelines regarding the molecular profiling of gliomas and other central nervous system cancers.
Addressing Skin Cancer: From Screening to TreatmentMay 20th 2023
In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.
Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCLMay 19th 2023
In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.
What is Optimal Donor Type for Patients With Cancer in Need of SCT?May 19th 2023
In an interview with Targeted Oncology, Salman Fazal, MD, discussed differences between older matched sibling donors vs younger unrelated donors in stem cell transplants and donor preferences at his institution for patients with cancer.